The proofreading potential of POLE is essential for ensuring replication fidelity, and its disruption by the pathogenic heterozygous mutations found in cancers leads to an ultra-hypermutated phenotype of tumours, with the highest burden of single-nucleotide variants among human cancers [6, 10, 11]. This evidence concerns the gene POLE and neoplasm.